In an effort to design dinuclear PtII compounds that maintain the target (DNA) binding profile of the trans-oriented dinuclear bifunctional PtII complexes containing aliphatic linker chains but are less susceptible to metabolic decomposition, the new, long-chain dinuclear PtII complexes—[{trans-PtCl(dien)}2-μ-(CH2)n]2+ (n = 7,10,12, dien = diethylenetriamine)—were synthesized. The toxicity of these metallodrugs was examined in ovarian tumor cell lines. The results showed that the activity of these complexes increased with growing length of the linker; the activity of complex containing the longest linker (n = 12) was comparable with that of cis-diamminedichloridoplatinum(II) (cisplatin). This observation correlated with the results of DNA binding studies performed in cell-free media. The results of these studies demonstrated that the growing length of the aliphatic bridge promoted more distorting conformational alterations induced in DNA. Attention was also paid to the reactivity of {[Pt(dien)Cl]2-alkane} compounds with glutathione (GSH). The results of these experiments support the thesis that the dinuclear structure of {[Pt(dien)Cl]2-alkane} complexes remains stable in the presence of S-containing compounds without undergoing chemical degradation as previously observed for some di/trinuclear bifunctional PtII complexes. This enhanced stability represents a favorable property which may contribute to reduce side effects and increase therapeutic efficacy of the dinuclear {[Pt(dien)Cl]2-alkane} compounds.
[1]
Bernhard Lippert,et al.
Cisplatin : chemistry and biochemistry of a leading anticancer drug
,
2006
.
[2]
Daniel C. Liebler,et al.
Elucidating mechanisms of drug-induced toxicity
,
2005,
Nature Reviews Drug Discovery.
[3]
Z. Siddik,et al.
Cisplatin: mode of cytotoxic action and molecular basis of resistance
,
2003,
Oncogene.
[4]
W. Zeller,et al.
Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells
,
1995,
Cell Biology and Toxicology.
[5]
B. Baguley.
DNA intercalating anti-tumour agents.
,
1991,
Anti-cancer drug design.
[6]
N. Farrell.
Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.
,
1993,
Cancer investigation.
[7]
B. Pullman,et al.
Molecular Basis of Specificity in Nucleic Acid-Drug Interactions
,
1990
.